This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Gentris Corporation Announces Changes To Board Of Directors

Stocks in this article: TZYM

MORRISVILLE, N.C., Sept. 7, 2011 /PRNewswire/ -- Gentris Corporation ( www.gentris.com), a global leader in applying genomic biomarkers to clinical studies, announced today that Dr. David J. Drutz will chair the Board of Directors.  Dr. Drutz, who has had a distinguished career in medicine, pharmaceuticals, biotechnology, and venture capital, joined the Gentris Board a year ago.  Tim Gupton, a highly experienced biopharma entrepreneur, and leader in accounting and finance, has also become a Board member.

Dr. Drutz, a board-certified internal medicine and infectious disease specialist, was formerly Professor of Medicine and Chief of Infectious Diseases at the University of Texas Health Science Center in San Antonio.  While in San Antonio, he founded and directed the NSF Center for Cell Regulation, an innovative public-private partnership focused on expanding research opportunities between academia and industry and enhancing local economic growth.

With an interest in commercial translation of new technologies, Dr. Drutz joined Smith Kline & French Laboratories in 1986 as a vice president and managed resources in both drug discovery and clinical research.  In 1990, he joined Daiichi Pharmaceutical Corporation, as the first U.S. employee, and built and managed both its clinical and regulatory areas.  Moving into biotechnology, Dr. Drutz assumed CEO positions at Sennes Drug Innovations ( Houston, TX) and Inspire Pharmaceuticals ( Durham, NC).  In 1999, he became a general partner in Pacific Rim Ventures Co., Ltd., a Japan-based venture capital firm, with subsequent investments in the U.S., Canada, Germany, the U.K., and Japan.

Dr. Drutz recently stepped down after eleven years as chairman of Tranzyme Pharma with the filing of its IPO, having been a co-founder of the company through his partnership in Pacific Rim Ventures.  Tranzyme (NASDAQ: TZYM), Durham, NC, is developing novel therapeutics for GI motility disorders.  He is also a director of two public companies (DARA Biosciences, Raleigh, NC, and MethylGene Inc., Montreal, Quebec, Canada) as well as another private company (Vaxin, Inc.; Birmingham, AL).  In addition, Dr. Drutz is a member of the Genome Canada Science and Industry Advisory Committee (SIAC).  Genome Canada, a not-for-profit organization established in February 2000, is mandated by the Government of Canada to develop and implement a national strategy for supporting large-scale genomics and proteomics research projects throughout the country.

Tim Gupton is a CPA and partner with Hughes, Pittman & Gupton, LLP ( http://www.hpg.com/partners/gupton) and former partner with KPMG.  He has had a broad cross-section of audit, tax, finance, and M&A responsibilities for companies in the biopharma, healthcare services, clinical research, lab services, and medical technology industries.  Mr. Gupton joined KPMG in 1972 and Hughes Pittman & Gupton, LLP, in 1992, where his practice has been centered on entrepreneurial business ventures, primarily in the life sciences industry.

Mr. Gupton has served as the start-up CFO for seven biopharmaceutical start-ups in the Research Triangle area.  He is currently the CFO for CoLucid Pharmaceuticals, which is developing a new migraine drug.  In addition to launching and managing start-ups, Mr. Gupton was a founder and general partner for Research Triangle Ventures, which is an investor in Gentris.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs